Open AccessPotential of nuclear magnetic resonance metabolomics in the study of prostate cancer
Author(s) -
Ramesh Reddy,
N. R. Jagannathan
Publication year - 2022
Publication title -
indian journal of urology/indian journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.333
H-Index - 30
eISSN - 1998-3824
pISSN - 0970-1591
DOI - 10.4103/iju.iju_416_21
Subject(s) - metabolomics , prostate cancer , medicine , sarcosine , choline , nuclear magnetic resonance spectroscopy , magnetic resonance imaging , prostate , magnetic resonance spectroscopic imaging , disease , hyperplasia , cancer , nuclear magnetic resonance , bioinformatics , pathology , biochemistry , chemistry , biology , radiology , glycine , physics , amino acid
Nuclear magnetic resonance (NMR) metabolomics is a powerful analytical technique and a tool which has unique characteristics and capabilities for the evaluation of a number of biochemicals/metabolites of cancer and other disease processes that are present in biofluids (urine and blood) and tissues. The potential of NMR metabolomics in prostate cancer (PCa) has been explored by researchers and its usefulness has been documented. A large number of metabolites such as citrate, choline, and sarcosine were detected by NMR metabolomics from biofluids and tissues related to PCa and their levels were compared with controls and benign prostatic hyperplasia. The changes in the levels of these metabolites aid in the diagnosis and help to understand the dysregulated metabolic pathways in PCa. We review recent studies on in vitro and ex vivo NMR spectroscopy-based PCa metabolomics and its possible role as a diagnostic tool.